Prosidyan® Targets the Orthopaedic Trauma Market with FIBERGRAFT Products
FIBERGRAFT® BG Morsels, FIBERGRAFT® BG Putty and FIBERGRAFT® BG Matrix
New Providence, NJ, August 19, 2021: Prosidyan, Inc. (www.prosidyan.com), developer of proprietary fiber-based bioactive glass bone graft substitute products, targets the Orthopaedic Trauma Market with its FIBERGRAFT BG product line. FIBERGRAFT BG products have been commercially available for over seven years and have been successfully implanted in patients worldwide.
“We are thrilled to reach this new milestone with our FIBERGRAFT BG product line. The Orthopaedic Trauma market is the perfect opportunity for us to increase the use of our FIBERGRAFT BG Morsels, FIBERGRAFT BG Putty and FIBERGRAFT BG Matrix products while expanding our current sales distribution channel,” said Charanpreet Bagga, CEO and Co-Founder of Prosidyan, New Providence, NJ.
FIBERGRAFT BG products are next generation synthetic bioactive bone graft substitutes used to assist in the healing of surgically created osseous defects and osseous defects created from traumatic injury to the bone. The clinically proven FIBERGRAFT BG products are manufactured with proprietary bioactive glass fibers that recruit bone-forming cells, attach these cells to its scaffold and connect them for cell proliferation– all of which enables robust bone formation1,2. Learn more about FIBERGRAFT BG products at https://www.prosidyan.com.
Prosidyan was founded in 2009 to develop a family of synthetic bioactive bone graft substitutes based on bioactive glass fibers. Prosidyan’s first product, FIBERGRAFT BG Morsels, a synthetic bone graft substitute, received FDA clearance in March 2014, and the first surgery utilizing this innovative bone graft substitute was performed in May 2014. The Company’s second product in the line, FIBERGRAFT BG Putty, received FDA clearance in March 2015, and comprises FIBERGRAFT BG Morsels in combination with Prosidyan’s proprietary bioactive carrier, OSSIGLIDE®. Prosidyan’s latest technology, FIBERGRAFT BG Matrix, which launched in August 2017, uses Prosidyan’s proprietary Type I collagen-based bioactive carrier.
Prosidyan is poised to revolutionize synthetic bioactive bone graft options globally, with numerous patents and a robust pipeline of products in development.
1 Prosidyan Data on File, DHF0002, DHF0003, DHF0006
2 “Novel Bioactive Glass Micro Fiber – Collagen Matrix Facilitates Posterolateral Spine Fusion.” WR. Walsh, PhD, Hyun Bae, MD. Innovative Technology Presentations, North American Spine Society 32nd Annual Meeting, Orlando, FL, October 25-28, 2017. Tracking Number: AM17NTABS00019